Skip to content

Net Income at other companies

Abbott logo
AbbottABT
$1.08B-18.7%
Boston Scientific logo
Boston ScientificBSX
$1.34B+99.3%
IAR
Integra LifeSciencesIART
-$4.62M+81.7%
Medtronic logo
MedtronicMDT
$1.24B+17.8%
Neuropace, Inc. logo
Neuropace, Inc.NPCE
-$6.69M-1.5%
AngioDynamics logo
AngioDynamicsANGO
-$8.08M-83.4%

Other financials

Income statement

See full
Revenue$12.1M+42.9%
Gross profit$7.8M+51.1%
Operating income-$8.5M-37.6%
EPS (diluted)-$0.32-45.5%

Balance sheet

See full
Cash & equivalents$36.5M+195%
Total debt$63.6M+1,750%
Total equity$18.8M-5.7%
Total assets$93.4M+211%

Cash flow

See full
Operating cash flow-$8.0M-29.1%
CapEx$645.0K+252%
Free cash flow-$8.6M-35.5%

Valuation

See full
Market cap$538.61M+69.2%
Enterprise value$565.68M+82.9%
P/S13.3×+3.4×

Profitability

See full
Gross margin62.3%+1.1pp
Operating margin-65.2%-1.9pp
Net margin-71.6%+8.8pp
FCF margin-65.7%+269pp

Returns & leverage

See full
Return on equity-149.7%+4,074pp
Debt / equity3.4×+3.2×
Current ratio5.8×+2.3×

Where this comes from

Reported directly by ClearPoint Neuro in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: ClearPoint Neuro’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about ClearPoint Neuro's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ClearPoint Neuro's net income?
ClearPoint Neuro (CLPT) reported net income of -$9.55M in Q1 2026.
How has ClearPoint Neuro's net income changed year-over-year?
ClearPoint Neuro's net income decreased by 58.5% year-over-year, from -$6.03M to -$9.55M.
What is the long-term trend for ClearPoint Neuro's net income?
Over 4 years (2021 to 2025), ClearPoint Neuro's net income has grown at a 15.4% compound annual growth rate (CAGR), from -$14.41M to -$25.54M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.